Xenon Pharmaceuticals Inc.
NASDAQ:XENEBiotechnology
-$0.29 today
- Market cap
- $3.69B
- Beta
- 0.63
- P/E (TTM)
- -12.1
- EPS (TTM)
- -$4.39
Volume 1.28M
Average 1.16M
Returns on capital
Xenon Pharmaceuticals Inc. management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
-59.5%
avg -35.0%
ROIC
-39.6%
avg -31.8%
ROA
-35.2%
avg -28.3%
Analysis
ROA is currently the strongest return metric at -35.2% versus its period average of -28.3%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
Ian C. Mortimer | President, Chief Executive Officer & Director | USD 1.38M | 50 | — | — |
Christopher John Kenney | Chief Medical Officer | USD 848.65K | 55 | 2 | <0.01% |
Andrea DiFabio | Chief Legal Officer & Corporate Secretary | USD 766.15K | 58 | 7.30K | <0.01% |
Darren S. Cline | Chief Commercial Officer | USD 619.77K | 62 | 20.00K | 0.03% |
Robin Sherrington | Executive Vice President of Strategy & Innovation | USD 587.03K | 65 | 65.00K | 0.08% |
Thomas Patrick Kelly | Chief Financial Officer | USD 515.7K | 55 | 22.50K | 0.03% |
James R. Empfield | Executive Vice President of Drug Discovery | USD 323.43K | 65 | 65.00K | 0.08% |
Matthew D. Ronsheim | Chief Operating Officer | — | 54 | — | — |
Colleen Alabiso | Senior Vice President of Corporate Affairs | — | — | — | — |
Shelley McCloskey | Executive Vice President of Human Resources | — | 66 | — | — |
Compensation is shown in the reported currency; data updated Nov 7, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Oct 15, 2026.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
2
$1.68M
Sells
26
$21.97M
Net Transaction Value
−$20.29M
Net selling
Most Active
MORTIMER IAN
18 transactions
Transactions sorted by date, descending.
| Type | |||
|---|---|---|---|
| Sep 30, 26Sep 30, 2026 | MORTIMER IAN Direct | Buy | $1.1M$1,121,400.00 |
| Sep 30, 26Sep 30, 2026 | Kelly Thomas Patrick Direct | Buy | $559.7K$559,740.00 |
| Aug 28, 26Aug 28, 2026 | KENNEY CHRISTOPHER JOHN Direct | Sell | $42.7K$42,683.62 |
| Aug 28, 26Aug 28, 2026 | KENNEY CHRISTOPHER JOHN Direct | Sell | $383.1K$383,145.37 |
| Aug 11, 26Aug 11, 2026 | GANNON STEVEN Direct | Sell | $640.6K$640,550.00 |
| Jun 5, 26Jun 5, 2026 | Cannon Gillian Direct | Sell | $63.2K$63,236.60 |
| Jun 5, 26Jun 5, 2026 | PATOU GARY Direct | Sell | $70.3K$70,251.08 |
| Mar 13, 26Mar 13, 2026 | DiFabio Andrea Direct | Sell | $74.1K$74,111.95 |
| Mar 13, 26Mar 13, 2026 | KENNEY CHRISTOPHER JOHN Direct | Sell | $77.9K$77,867.25 |
| Mar 13, 26Mar 13, 2026 | MORTIMER IAN Direct | Sell | $403.6K$403,584.30 |
1–10 of 28
Summary
Insiders reported 2 buys worth $1.68M and 26 sells worth $21.97M over the last 12 months. That adds up to net selling of $20.29M. MORTIMER IAN was the most active insider with 18 transactions.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A4 analysts |
| Revenue | N/A | N/A | -7.4% | +166.4% (5yr)6 analysts |
| Net Income | N/A | N/A | N/A | N/A6 analysts |
| EBIT | N/A | N/A | N/A | N/A6 analysts |
Analysis
Recent growth has been strongest in Revenue at -7.4% over three years. Forward estimates point to Revenue at +166.4% (5yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Who does Xenon Pharmaceuticals Inc. compete with?
Open similar companies to compare how their management teams allocate capital.
Competitors
Peer companies in the same sector
Questions
Management questions
Common questions about XENE's management, answered from reported figures.
Who manages XENE?
Xenon Pharmaceuticals Inc. (XENE) lists 10 active executives. The top listed executive is Christopher John Kenney, Chief Medical Officer.
Are XENE insiders buying or selling?
Recent insider activity shows net buying of $73.90M.
Continue the stock analysis
Jump to another research area for this company.